Xilio Therapeutics, Inc.
XLO
$0.6998
-$0.0182-2.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 242.98% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 242.98% | -- | -- | -- | -- |
| Cost of Revenue | 36.68% | -- | -- | -- | -- |
| Gross Profit | 18.21% | -- | -- | -- | -- |
| SG&A Expenses | 22.44% | 38.70% | 1.92% | -0.05% | -15.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.82% | 1.46% | -15.32% | -1.70% | -15.34% |
| Operating Income | 2.10% | 16.25% | 24.83% | 14.73% | 27.05% |
| Income Before Tax | -13.78% | 22.89% | 25.84% | 16.29% | 28.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.78% | 22.89% | 25.84% | 16.29% | 28.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.78% | 22.89% | 25.84% | 16.29% | 28.05% |
| EBIT | 2.10% | 16.25% | 24.83% | 14.73% | 27.05% |
| EBITDA | 1.71% | 17.04% | 25.04% | 14.67% | 27.49% |
| EPS Basic | 3.50% | 71.18% | 68.41% | 63.70% | 55.04% |
| Normalized Basic EPS | 3.29% | 69.51% | 68.41% | 63.58% | 55.13% |
| EPS Diluted | 3.50% | 71.18% | 68.41% | 63.70% | 55.04% |
| Normalized Diluted EPS | 3.29% | 69.51% | 68.41% | 63.58% | 55.13% |
| Average Basic Shares Outstanding | 17.92% | 167.62% | 134.70% | 130.58% | 60.01% |
| Average Diluted Shares Outstanding | 17.92% | 167.62% | 134.70% | 130.58% | 60.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |